Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of semaglutide injection in Chinese patients with type 2 diabetes mellitus
CTR20242569Phase 3Completed
- Sponsor
- China Resources Double-Crane Pharmaceutical
- Start
- Jul 2024
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of semaglutide in type 2 diabetes mellitus (T2DM), sponsored by China Resources Double-Crane Pharmaceutical. Started Jul 2024; status: completed.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on CTR20242569.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20242569.